Epoprostenol for Frostbite

(ECCO Trial)

This trial tests the effectiveness and safety of epoprostenol for treating severe frostbite injuries. Frostbite can cause serious damage, sometimes leading to amputation. The study aims to determine if epoprostenol can improve recovery by increasing blood flow and preventing clotting. Participants will receive either epoprostenol or a placebo (a harmless substance with no treatment effect) along with standard care to compare results. Ideal participants are those admitted to the University of Colorado Hospital with a Cauchy Grade 2-4 frostbite injury within 72 hours of rewarming. As a Phase 4 trial, this research focuses on understanding how the already FDA-approved and effective treatment benefits more patients, offering participants a chance to contribute to valuable medical insights.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently taking or planning to take other prostaglandin analogs like iloprost or treprostinil.

Research has shown that epoprostenol is generally safe for patients. Studies have found no new safety issues, and most people can use it. Epoprostenol works by widening blood vessels, improving blood flow to areas in need. This is crucial for conditions like frostbite, where cold exposure reduces blood supply.

Unlike other treatments for frostbite, Epoprostenol offers a new approach by using a powerful vasodilator that helps improve blood flow. Most treatments for frostbite focus on rewarming the affected area and preventing infection, but Epoprostenol works by expanding blood vessels and potentially restoring circulation to damaged tissues more effectively. Researchers are excited about this treatment because it could lead to faster recovery and better outcomes for frostbite patients by directly targeting blood flow issues that are central to tissue damage in frostbite.

Research has shown that epoprostenol might help treat severe frostbite. It widens blood vessels and prevents blood cells from clumping, improving blood flow to affected areas. In this trial, some participants will receive an intravenous infusion of epoprostenol alongside standard care. One study found that inhaled epoprostenol significantly increased skin temperature in cold conditions. Another study found that a similar drug, iloprost, helped prevent amputations in frostbite patients. These findings suggest that epoprostenol could be a promising option for managing severe frostbite injuries.¹³⁴⁶⁷